Slide 1: Acquisition of NeoTract, Inc. Conference Call
Teleflex Incorporated Acquisition of NeoTract, Inc. Conference Call September 5, 2017 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and our discussion contain forward-looking information and statements. These forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected or implied in the forward-looking statem
Slide 3: Agenda
Agenda 1. Strategic Rationale 2. Transaction Overview 3. NeoTract, Inc. Overview 4. Financial Summary 5. Transaction Summary 3
Slide 4: Strategic Rationale
Strategic Rationale Highly strategic and complementary acquisition − Significantly advances Teleflex’s offering of urological solutions − Single-product company with growth profile better than Vidacare − Expands Teleflex’s product portfolio into benign prostatic hyperplasia (“BPH”) market estimated
Slide 5: Strategic Rationale
Strategic Rationale Strong clinical data and intellectual property and established reimbursement − Since receipt of CE Mark in 2010 and de novo 510(k) in 2013, NeoTract’s UroLift® System has been the subject of a significant number of studies, including: 9 studies, including two randomized studies
Slide 6: Transaction Overview
Transaction Overview Price • Upfront payment of $725 million at closing and up to an additional $375 million upon the achievement of 2018 through 2020 commercial sales milestones Integration • Proven track-record of successfully integrating acquisitions and quickly de- levering Timing • Subject to r
Slide 7: NeoTract, Inc. Overview
NeoTract, Inc. Overview Business Overview • Founded in 2004, NeoTract is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift® System • The UroLift® System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to beni
Slide 8: Most men who suffer from moderate to severe BPH experience a reduction in quality of life
Most men who suffer from moderate to severe BPH experience a reduction in quality of life - Disruption of sleep patterns ¢ Impaired sex life ¢ Interruption of leisure activities * Negative impact on job performance ¢ Can lead to social isolation and depression 8 TelefleEsxc
Slide 9: BPH Becomes Increasingly Common as Men Age
NS BPH Becomes Increasingly Common as Men Age Percentage of Men with Histological BPH' Men in 50s Men in 80s % 90% % 40% U.S. men with moderate to severe symptoms? 1. Ber ae logy 1984; (Ee 474-479 2. i= ed on Wei, et al., Urologic Dis: ica, NIH publication 07-5512: 43-67 and US Census population est
Slide 10: BPH is the Number One Reason Men Visit a Urologist
BPH is the Number One Reason Men Visit a Urologist Top 10 Reasons for Visits to Urologists2 • ~12,000 urologists in the U.S.1 • ~47% of all BPH patients are BPH Surgery Follow Up in the care of a urologist1 Prostate Cancer Penis Disorder, Other • Initial focus on ~5,400 Specific Exam, Other urologis
Slide 11: >$30B Market Opportunity for UroLift in the U.S.
>$30B Market Opportunity for UroLift® in the U.S. 0.3 Surgery 1.5 Drug Drop Out 8.5 Million Drugs Men On Drugs or Drug Drop Out 7.0 UroLift® Target Market 3.2 Watchful Waiting #Men (Millions) 12.0 Million U.S. Men Treated for BPH1 66% UroLift® patients are coming from the Watchful Waiting, Drug and
Slide 12: Simple, Straightforward Procedure
The UroLift ® System Simple, Straightforward Procedure Nitinol Capsular Tab PET Suture Stainless Steel Urethral End Piece Apply Lidocaine Gently Push Relieve Jelly/Oral Sedative Tissue Aside Obstruction Insert Delivery System Deploy Customized Implants Typically Same Day (4-6 Avg) Discharge 12
Slide 13: Financial Summary
Financial Summary 1. Subsequent to issuing Q2’17 financial results and prior to entering into the agreement to acquire NeoTract, Teleflex used $475 million of cash on the balance sheet to reduce its outstanding borrowings under its revolving credit facility, reducing Q2’17 LTM pro-forma gross levera
Slide 14: Transaction Summary
Transaction Summary 1. Highly strategic, complementary and accretive acquisition 2. Accelerates Teleflex’s sales growth trajectory and provides significant sales channel opportunity 3. NeoTract’s UroLift® System has strong clinical data and intellectual property, as well as established reimbursement
Slide 15: Teleflex
TelefleEsxc